Literature DB >> 10847711

Combined central retinal vein occlusion and cilioretinal artery occlusion in a patient on hormone replacement therapy.

D C Murray, D Christopoulou, M Hero.   

Abstract

Entities:  

Mesh:

Year:  2000        PMID: 10847711      PMCID: PMC1723466          DOI: 10.1136/bjo.84.5.546e

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


× No keyword cloud information.
  7 in total

1.  Radial optic neurotomy in combined cilioretinal artery and central retinal vein occlusion.

Authors:  S Mennel; K Droutsas; C H Meyer; J C Schmidt; P Kroll
Journal:  Br J Ophthalmol       Date:  2005-05       Impact factor: 4.638

2.  TESTOSTERONE SUPPLEMENTATION AND RETINAL VASCULAR DISEASE.

Authors:  Vaidehi S Dedania; David N Zacks; Wei Pan; Brian L VanderBeek
Journal:  Retina       Date:  2018-11       Impact factor: 4.256

3.  Combined central retinal vein and cilioretinal artery occlusion.

Authors:  Giuseppe Querques; Francesco Prascina; Gian-Marco Sarra; Cristiana Iaculli; Nicola Delle Noci
Journal:  Int Ophthalmol       Date:  2007-06-15       Impact factor: 2.031

4.  Cardiovascular risk factors in patients with combined central retinal vein occlusion and cilioretinal artery occlusion: Case report.

Authors:  Andrzej Grzybowski; Waldemar Elikowski; Magdalena Gaca-Wysocka
Journal:  Medicine (Baltimore)       Date:  2018-01       Impact factor: 1.889

5.  Thrombophilia and retinal vascular occlusion.

Authors:  Charles J Glueck; Robert K Hutchins; Joel Jurantee; Zia Khan; Ping Wang
Journal:  Clin Ophthalmol       Date:  2012-08-28

6.  Comorbidities in combined retinal artery and vein occlusions.

Authors:  Dieter Schmidt
Journal:  Eur J Med Res       Date:  2013-08-16       Impact factor: 2.175

Review 7.  Gender differences in ocular blood flow.

Authors:  Doreen Schmidl; Leopold Schmetterer; Gerhard Garhöfer; Alina Popa-Cherecheanu
Journal:  Curr Eye Res       Date:  2014-06-03       Impact factor: 2.424

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.